News | TCT | September 15, 2022

Valentin Fuster, M.D., Ph.D., Receives Prestigious Award from Cardiovascular Research Foundation

Dr. Valentin Fuster to be honored with the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award. Image courtesy of Mount Sinai Health System

Dr. Valentin Fuster to be honored with the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award. Image courtesy of Mount Sinai Health System 


September 15, 2022 — The Cardiovascular Research Foundation (CRF) will honor Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, with the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Career Achievement Award

Dr. Fuster will receive this award September 17, at the 34th annual TCT scientific symposium, sponsored by CRF. The TCT Career Achievement award recognizes Dr. Fuster’s extraordinary contributions to the field of interventional cardiology and transformation of patient care through his career endeavors, research pursuits, and mentorship of others.
“I am grateful for this award and would like to recognize all the contributors who have inspired my work,” says Dr. Fuster.
Dr. Fuster's contributions to cardiovascular medicine and the prevention and treatment of heart disease globally are unparalleled. He has 35 worldwide honorary degrees and is the most highly cited Spanish research scientist of all time, according to Google Scholar. He is an author of more than 900 scientific articles in international medical journals and has published two leading books on clinical cardiology and research. Dr. Fuster has received three of the most important awards from the National Institutes of Health and is the only cardiologist to have received the highest awards for research from the four leading international cardiology organizations: the American College of Cardiology, American Heart Association (AHA), European Society of Cardiology, and Interamerican Society of Cardiology. He recently received Thailand’s Prince Mahidol Award in the field of Medicine, and this year, the AHA established the “Valentin Fuster Award for Innovation in Science” in his honor, naming him the first recipient. 

Dr. Fuster is Editor-in-Chief of the Journal of the American College of Cardiology (JACC), which ranks among the top cardiovascular journals in the world for its scientific impact. He is a past president of both the AHA and the World Heart Federation. He the General Director of the Spanish National Center for Cardiovascular Research (CNIC).  Dr. Fuster is a member of the National Academy of Medicine, where he served as chair of the Committee on Preventing the Global Epidemic of Cardiovascular Disease, and was a Council member of the National Heart, Lung, and Blood Institute. Dr. Fuster was also President of the Training Program of the American College of Cardiology. 

For more information: https://www.mountsinai.org 

Find more TCT22 coverage here  


Related Content

News | Heart Failure

September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in ...

Home September 29, 2022
Home
News | Heart Failure

September 28, 2022 — A University of Massachusetts Amherst nurse engineer is leading a team of researchers who are ...

Home September 28, 2022
Home
News | Heart Failure

September 19, 2022 — A first-in-human (FIH) study using the ModulHeart device (Puzzle Medical Devices Inc.) has ...

Home September 19, 2022
Home
News | Heart Failure

September 15, 2022 — Today, aortic stenosis (AS) is one of the most common and serious valve disease problems [1]. It ...

Home September 15, 2022
Home
News | Heart Failure

September 14, 2022 — Minimally invasive, catheter-based transcatheter aortic valve replacement (TAVR) has revolutionized ...

Home September 14, 2022
Home
News | Heart Failure

September 2, 2022 — Dapagliflozin reduces the risk of cardiovascular death or worsening heart failure in heart failure ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure ...

Home September 02, 2022
Home
News | Heart Failure

August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) ...

Home August 29, 2022
Home
News | Heart Failure

August 24, 2022 — Patients diagnosed with moderate aortic stenosis and congestive heart failure may qualify to ...

Home August 24, 2022
Home
Subscribe Now